Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 8, 2026.
The European Prevention of Alzheimer's Dementia (EPAD) project is an initiative funded by the Innovative Medicines Initiative, established to overcome major hurdles in drug development for the secondary prevention of Alzheimer's dementia. It conducts the EPAD Longitudinal Cohort Study (LCS) and a Bayesian adaptive designed EPAD Proof-of-Concept (PoC) trial. Its core objectives are to build a readiness cohort for the PoC trial and to generate a comprehensive, large dataset for disease modeling of preclinical and prodromal Alzheimer's disease.
Optimly has not yet published enough evidence to assess how often AI assistants recommend Epad European Prevention Of Alzheimer S Dementia Spain Eu Uk.
Optimly has not yet published a supported competitor set for Epad European Prevention Of Alzheimer S Dementia Spain Eu Uk.
Official website: https://pubmed.ncbi.nlm.nih.gov/
Last analyzed: August 8, 2026
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile